anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: chemistry. ^ SUBSTANCE: method involves steps for grinding cellulose ether and a cationic surfactant in a mill and, optionally, drying the mixture. Cellulose ether contains water in amount of 20-90% of total weight of the cellulose ether and water. The cationic surfactant is present in amount of 0.001-2% of the total weight of the mixture. The cationic surfactant is a quaternary ammonium compound. Drying is carried out while grinding, before the grinding step or after the grinding step. The method enables to obtain a product with low dust explosion hazard. ^ EFFECT: obtained cellulose ether is used in cement, gypsum and coating compositions as a thickener and as binder in paints and pharmaceutical preparations. ^ 7 cl, 1 ex
The present invention provides a composition and a method both for treating or preventing atopic dermatitis effectively. Provided is a composition which contains an acetylcholine inhibitor, e.g., an anticholinergic substance, as an active ingredient. Also provided is a method which includes a step of administering an acetylcholine inhibitor such as an anticholinergic substance. The detailed mechanism of the development of atopic dermatitis has not been elucidated so far. Therefore, it has been difficult to treat atopic dermatitis effectively. The composition according to the present invention can treat atopic dermatitis effectively through the inhibition of the action of acetylcholine.
Guhong injection (GHI) has been applied in the therapy of cardio-cerebrovascular disease in clinic, but there is no report about the pharmacokinetic/pharmacodynamic (PK/PD) research on GHI treating myocardial ischemia/reperfusion (MI/R) injury in rats. In this study, eight compounds of GHI in plasma, including N-acetyl-L-glutamine (NAG), chlorogenic acid (CGA), hydroxysafflor yellow A (HSYA), p-coumaric acid ( pCA), rutin, hyperoside, kaempferol-3-O-rutinoside, and kaempferol-3-O-glucoside, were quantified by LC-MS/MS. We discovered that the values of t1/2β, k12, V2, and CL2 were larger than those of t1/2α, k21, V1, and CL1 for all compounds. The levels of four biomarkers, creatine kinase-MB (CK-MB), cardiac troponin I (cTn I), ischemia-modified albumin (IMA), and alpha-hydroxybutyrate dehydrogenase (α-HBDH) in plasma were determined by ELISA. The elevated level of these biomarkers induced by MI/R was declined to different degrees via administrating GHI and verapamil hydrochloride (positive control). The weighted regression coefficients of NAG, HSYA, CGA, and pCA in PLSR equations generated from The Unscrambler X software (version 11) were mostly minus, suggesting these four ingredients were positively correlated to the diminution of the level of four biomarkers. Emax and ED50, two parameters in PK/PD equations that were obtained by adopting Drug and Statistics software (version 3.2.6), were almost enlarged with the rise of GHI dosage. Obviously, all analytes were dominantly distributed and eliminated in the peripheral compartment with features of rapid distribution and slow elimination. With the enhancement of GHI dosage, the ingredients only filled in the central compartment if the peripheral compartment was replete. Meanwhile, high-dose of GHI generated the optimum intrinsic activity, but the affinity of compounds with receptors was the worst, which may be caused by the saturation of receptors. Among the eight analytes, NAG, HSYA, CGA, and pCA exhibited superior cardioprotection, which probably served as the pharmacodynamic substance basis of GHI in treating MI/R injury.
Polymeric compounds which have carboxylic acid ester end-capping groups and, preferably a poly(alkoxy) backbone, are used to reduce the hydrolytic enzyme activity of hydrolytic enzymes such as lipase, in particular the lipase enzyme activity of micro-organisms, such as Staphilococcus aureus. These polymers are substantially non-hydrolysable by such enzymes and are used in compositions, in particular, for the reduction of skin rash or irritation, acne, dandruff formation and malodour of the body, and for increase of the longevity of perfumes and for the preservation of food and beverage products. The preferred polymeric compounds are Pluronic (RTA) copolymers or Synperonic (RTA) copolymers, also known as poloxamers, which are copolymers of poly(ethyleneoxy) and poly(propyleneoxy) and/or poly(butyleneoxy) compounds, for example Pluronic 6800, 9200, 9400 and 10500; Synperonic 81, 42 and 25R2 which have been subjected to an end-capping reaction so that two such end caps are present in each polymer macromolecule. The preferred ester end-capping groups are the alkyl acid esters derived from formic or acetic acid. These compositions may be applied directly to a local area of skin or they may be applied via the use of a disposable absorbent article such as a bandage, plaster or diaper. The polymers may be prepared by heating the polymer.
The invention discloses a Chinese medicinal preparation for treating suppurative otitis media, and the Chinese medicinal preparation is mainly used for treating the suppurative otitis media. The preparation is mainly prepared from 30 grams of kuh-seng, 10 grams of borneol and 25 grams of sesame oil. The sesame oil is accommodated by using a pot, put over fire and boiled, the kuh-seng is immediately put and fished out after being brown, the borneol is put, and the components are stirred uniformly and cooled for later use. The preparation is dropped into ears for three times every day, and 2 to 3 drops are used every time. The suppurative otitis media can be healed in three days. The Chinese medicinal preparation for treating the suppurative otitis media is simple in formula and remarkable in treatment effect, does not have side effect, and is low in cost, convenient to administrate and convenient to popularize and apply.
Participants in arm 1 are grouped as lactose digesters based on genetic analysis and breath hydrogen results. In discrepant cases the genetic status is accepted. Arm 1 is initially withdrawn from dairy foods(lactose) and then asked to consume lactose 50g in divided doses mixed in water for 2 weeks.
The present invention relates to a Chinese medicine composition for curing spurs and hyperosteogeny, and a preparation method thereof. The composition comprises the raw materials of pueraria root, chuanxiong rhizome, safflower, notopterygium root, peach seed, twotooth achyranthes root, pawpaw, curcuma, white peony root, liquorice, asarum, fresh ginger, fibraurea recisa, garden balsam stem, borneol, white mustard seed, eucommia bark, raw wild aconite, clematis root and musk powder. During preparation, the pueraria root, the chuanxiong rhizome, etc. are respectively washed, crushed and evenly mixed. Alcohol is added for leaching. After centrifugal separation, supernatant liquid is obtained. A penetrating agent is added for even mixing. The product has the characteristics of convenient use, low cost, safety, high efficiency, no toxic or side reaction, good medicine effect, low dose, obvious effect when penetrating into affected parts, etc. The effective rate reaches 100% and the cure rate reaches 95%.
OBJECTIVE: Meningiomas are the most common primary brain tumors in adults and a subset are aggressive lesions resistant to standard therapies. Laser interstitial thermal therapy (LITT) has been successfully applied to other brain tumors, and recent work aims to explore the safety and long-term outcome experiences of LITT for both new and recurrent meningiomas. The authors' objective was to report safety and outcomes data of the largest cohort of LITT-treated meningioma patients to date.
METHODS: Eight United States-based hospitals enrolled patients with meningioma in the Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN) prospective multicenter registry and/or contributed additional retrospective enrollments for this cohort study. Demographic, procedural, safety, and outcomes data were collected and analyzed using standard statistical methods.
RESULTS: Twenty adult patients (12 prospective and 8 retrospective) with LITT-targeted meningiomas were accrued. Patients underwent LITT for new (6 patients) and recurrent (14 patients) tumors (ranging from the 1st to 12th recurrence). The 30-day complication rate was 10%. Twenty percent of patients (4/20) had exhausted all other treatment options. Median length of follow-up was 1.3 years. One-third of new (2/6) and one-half of recurrent (7/14) meningiomas had disease progression during follow-up. One-year estimated local control (LC), progression-free survival, and overall survival rates were 55.3%, 48.4%, and 86.3%, respectively. In the 12 patients who had ≥ 91% ablative coverage, 1-year estimated LC was 61.4%. The complication rate was 10% (2/20), with 1 complication being transient and resolving postoperatively.
CONCLUSIONS: This cohort study supports the safety of the procedure for this tumor type. LITT can offer a much-needed treatment option, especially for patients with multiply recurrent meningiomas who have limited remaining alternatives.
All patients received oral and written instructions on the appointment day. All patients were instructed to have low-residue food for lunch and dinner on the day before colonoscopy. Patients were instructed to begin drinking the first 1.5L-2L PEG at 7:00-9:00 PM on the day before colonoscopy. On the day of the procedure, they took another 1.5L-2L 4-6 hours before colonoscopy. Patients were encouraged more to drink more clear liquids after purgatives for adequate hydration.
Sit muscle strength training using a sand bag grip ball conducted twice a week. Each exercise session will begin and end with a 5-15 minute warm-up and cool-down routine. The exercise program consists of 20-40 minute chair-based resistance exercises.
An anti-stress extract which contains an Astragali radix extract normalizes the functional variation of adrenal gland and spleen. A composition for relieving stress generated in a body comprises an Astragli radix extract as an active ingredient. The content of the Astragli radix extract is 0.01-30%(w/w). The Astragli radix extract is one among extract by cold water, extract by hot water and extract by the ethanol. The content of ethanol in ethanol solution is 5-75%(v/v). The composition is food. An anti-cotisol composition comprises the Astragli radix extract as an active ingredient.
The KHENERFIN study is investigating whether the study medicine, sonlicromanol, is able to improve symptoms of fatigue and the impact of fatigue on daily life, and whether sonlicromanol is able improve physical abilities of people living with mitochondrial disease such as balance control and lower limb skeletal muscle strength. Additionally, the study evaluates the efficacy of sonlicromanol on selected secondary and exploratory outcome measures, as well as the safety and tolerability of sonlicromanol. This study is a placebo controlled, double blind study; the effects of sonlicromanol will be compared with a placebo (study medication that looks like the actual study medicine but contains no active medicine). Neither the participants nor the study team know who is receiving the study medicine or placebo and participants are not able to change which treatment they are assigned.

During the screening period, which lasts a maximum of 6 weeks, it is assessed whether the potential participant meets all requirements to participate in the study. Patients who complete the screening phase and are enrolled in the study are randomly (by chance) assigned to receive either the study medicine sonlicromanol or placebo (no active medication). Participants have an equal chance of receiving either sonlicromanol or a placebo. A final follow-up visit is scheduled 2 weeks after taking the last dose of study medication. Total study duration is approximately 60 weeks. The study medicine (as well as placebo) is a powder that is dissolved in water and must be taken twice daily during the treatment period of 52 weeks. A total of 150 patients with a confirmed mitochondrial DNA tRNALeu(UUR) 3243A\>G mutation will participate in this study.
PURPOSE:To efficiently supply the liq. medicine by driving a liq. medicine molecule by utilizing electrostatic force or ultrasonic vibration, and adjusting a transmission action of the liq. medicine molecule which transmits to the outside of a liq. medicine leading-out means from a liq. medicine supply part. CONSTITUTION:In the tip part of a catheter part 2, a DC current is subjected to electric conduction between a first electrode 9 and a second electrode 10 from a DC power source 8. Therefore, since a liq. medicine molecule in a liq. medicine ionized to the same polarity as a first electrode 9 is sucked electrically to the direction of a second electrode 10 side from a first electrode 9 side by electrostatic force, the liq. medicine of the inside of the catheter part 2 can be supplied efficiently to the target part in the body by transmitting through a liq. medicine transmissive film 6. Therefore, at the time of supply work of the liq. medicine, the injection quantity of the liq. medicine molecule can be controlled by adjusting a voltage between a first and a second electrodes 9, 10 by an electric conduction from the DC power source 8. In such a way, the supply work of the liq. medicine can exactly and efficiently be executed.
This is a phase 1b study of P30-linked EphA2, CMV pp65, and survivin vaccination (collectively called the P30-EPS vaccine) in HLA-A\*0201 positive patients with a newly diagnosed, unmethylated, and untreated World Health Organization (WHO) grade IV malignant glioma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke, is planned to address the following primary objective: Evaluate the safety profile of a cancer vaccine comprised of P30-linked EphA2, CMV pp65, and survivin peptides.

A maximum of 36 patients with a newly diagnosed, previously untreated WHO grade IV malignant glioma that is MGMT promoter unmethylated will be treated in this study after undergoing standard of care surgical resection followed by 6 weeks of radiation therapy (XRT) with concomitant temozolomide (TMZ) and providing informed consent. Patients will receive seven P30 linked-EphA2, -CMV pp65, and -survivin (P30-EPS) peptide vaccines over two phases. The first 5 will be given during the Priming Phase (day 1 through day 22). The final 2 will be given during the Booster Phase (day 84 \[± 2 days\] and day 140 \[± 2 days\]). During the Booster Phase on Day 84, patients will also be given 20ug/kg Hiltonol® injections to administer at home every 2 weeks until they return on Day 140. Blood will be drawn throughout the study to investigate the immune response to P30-EPS vaccination. The study will enroll two patient strata: patients who are CMV seronegative and patients who are CMV seropositive. Within each stratum, cohorts of 3 patients will initially be accrued to the study to assess the toxicity associated with the vaccine. The starting dose of P30-EPS is 300 μg/peptide/dose, and the dose will be escalated to 400 μg/peptide/dose. In the event of unacceptable dose-limiting toxicity, the dose will be de-escalated to 200 μg/peptide/dose (dose level minus one). Acute toxicity monitoring will focus on dose-limiting toxicities, as defined in Section 9.1.2 of the protocol, occurring between vaccine 1 and 30 days after vaccine 5. The most common side effects of peptide vaccines are redness or swelling at the injection site, local changes to the texture of your skin (hardening) at the injection site, itching, allergic reactions, and a potentially serious side effect called cytokine release syndrome. The most common side effects of Hiltonol® are reactions at the injection site and flu-like symptoms.
Test Group_ A premixed CaSi-containing bioceramic sealer (Ah Plus Bioceramic, Dentsply, Konstanz, Germany) was used in association with a warm carrier-based technique (Thermafil, Dentsply, Konstanz, Germany). AH Plus Bioceramic is mostly composed of zirconium dioxide (50-70%) as a radiopacifier and tricalcium silicate (10-15%) as a bioactive component. Dimethyl sulfoxide and traces of lithium carbonate and thickening agents are also reported by the manufacturer.The sealer was inserted in the canal and the carrier was warmed in a dedicated oven (thermaprep) and inserted within 60 seconds.
Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.
the invention pertains in part to the development of a vaccine for poultry against necrotic enteritis (NE). The vaccine utilizes a protective antigen that is a mutated, full-length, non-toxic Clostridium perfringens alpha-toxin protein (Mcpa). Utility of the vaccine was demonstrated by reduction of lesion severity in NE challenge trails, for example. Also disclosed herein are novel approaches for producing the vaccine in significant quantities. One exemplified approach involves producing NE vaccine (mutated alpha toxin) in bacterial expression systems, preferably utilizing the Pseudomonas fluorescens system, for commercial use in controlling NE in the poultry industry. The subject vaccines can be administered preferably to chickens in several different ways. A novel, Type VI alpha toxin from chicken isolates of Cp is also disclosed.
INTRODUCTION: A nationwide multicenter study was performed to examine whether there is a correlation between decrease in tissue resistance and time to local tumor recurrence after irreversible electroporation (IRE) in patients with hepatocellular carcinoma (HCC) and colorectal cancer liver metastases (CRCLM).
METHODS: All patients treated with IRE for liver tumors in Sweden from 2011 until 2018 were included. Patient characteristics and recurrence patterns were obtained from medical records and radiological imaging. All procedural data from the IRE hardware at the three hospitals performing IRE were retrieved. The resistance during each pulse and the change during each treatment were calculated. The electrode pair with the smallest decrease in tissue resistance was used and compared with the time to LTP.
RESULTS: 149 patients with 206 tumors were treated. Exclusion due to missing and inaccurate data resulted in 124 patients with 170 tumors for the analyses. In a multivariable Cox regression model, a smaller decrease in tissue resistance and larger tumor size were associated with shorter time to local tumor recurrence for CRCLM, but not for HCC.
CONCLUSION: There was an association between a decrease in tissue resistance and time to local tumor recurrence for CRCLM. The decrease in resistance, in combination with a rise in current, may be the parameters the interventionist should use during IRE to decide if the treatment is successful.
PROBLEM TO BE SOLVED: To obtain a cosmetic comprising a granule formulated therein and having raised long-term stability of the granulated granule by including an oily base in which the principal ingredient of the constituent ingredients is a hydrocarbon-based oil and the granulated granule comprising zinc white formulated therein. SOLUTION: This cosmetic is obtained by formulating (A) an oily base comprising a hydrocarbon-based oil with (B) a granular powder granulated with an oil-based binder and comprising zinc white. For example, the hydrocarbon- based oil of the ingredient A is a liquid paraffin and is preferably contained in an amount of 0.1-99 wt.% based on the cosmetic comprising the granule formulated therein. The oil-based binder of the ingredient B means a binder influenced by dissolution, softening, swelling, etc., in the hydrocarbon-based oil and is, e.g. ethyl cellulose. The binder is granulated with a powder prepared by formulating zinc white so as to provide preferably 0.1-30 wt.% based on the total amount of the granulated granule.  Thereby, the granular powder of the ingredient B is obtained and is preferably contained in an amount of 0.01-10 wt.% based on the cosmetic comprising the granule formulated therein.
BACKGROUND AND OBJECTIVE: Cervical lymph node metastasis (CLNM) is considered a marker of papillar Fethicy thyroid cancer (PTC) progression and has a potential impact on the prognosis of PTC. The purpose of this study was to screen for predictors of CLNM in PTC and to construct a predictive model to guide the surgical approach in patients with PTC.
METHODS: This is a retrospective study. Preoperative dual-energy computed tomography images of 114 patients with pathologically confirmed PTC between July 2019 and April 2023 were retrospectively analyzed. The dual-energy computed tomography parameters [iodine concentration (IC), normalized iodine concentration (NIC), the slope of energy spectrum curve (λHU)] of the venous stage cancer foci were measured and calculated. The independent influencing factors for predicting CLNM were determined by univariate and multivariate logistic regression analysis, and the prediction models were constructed. The clinical benefits of the model were evaluated using decision curves, calibration curves, and receiver operating characteristic curves.
RESULTS: The statistical results show that NIC, derived neutrophil-to-lymphocyte ratio (dNLR), prognostic nutritional index (PNI), gender, and tumor diameter were independent predictors of CLNM in PTC. The AUC of the nomogram was .898 (95% CI: .829-.966), and the calibration curve and decision curve showed that the prediction model had good predictive effect and clinical benefit, respectively.
CONCLUSION: The nomogram constructed based on dual-energy CT parameters and inflammatory prognostic indicators has high clinical value in predicting CLNM in PTC patients.
PURPOSE: To obtain an agent and food containing chlorella as an active compo nent, capable of inhibiting the absorption of lipid contained in a food into a body and at the same time stimulating the extrusion of lipid absorbed in a body, and accordingly enabling the prevention of hypercholestrerolemia and obesity. CONSTITUTION: These are a liquid absorption inhibiting and extrusion stimulating agent containing chlorella as an active component and a high fat food containing chlorella. The chlorella is preferably Chlorella regularis, Chlorella vulugaris, Chlorella pyrenoidosa, etc., which are easily available and excellent in safety. Further, the agent is preferably taken orally before, during or after a meal, and it is preferably administered at a deily dose of about 4-8g for an adult in a usual case. Furthermore, the mixing of the agent to a high fat food having a fat content of about >=10% (e.g. hamburg or ice cream) allows a heart disease patient, etc., to enjoy the high fat food without worrying about the troubles of the excess taking of fat.
All patients will receive osimertinib 80mg orally daily. Patients receive Carboplatin (AUC 5 IV q 3 weeks) and Pemetrexed (500mg/m2 IV q 3 weeks) for a total of 4 cycles followed by pemetrexed maintenance from cycle 8 onwards. Patients will be required to complete a pill diary beginning at Cycle 4.